Get started

BIOC

BIOC A safe and excellent opportunity by all standardsWhat the global atmosphere is witnessing is the escalation of the new monkey epidemic, and also the raising of drug prices in Egypt by a decision of the Egyptian Medicine Authority. Entering the diverse winter season can be more difficult than summer is a paradise for Egyptian pharmaceutical companies listed on the Egyptian Stock Exchange From my personal experience, I exited gold today on the date of publication of this theory, and tomorrow I will buy an amount of shares amounting to 10 thousand shares. I put this process into history for success or otherwise, and I hope to achieve 25 to 30% returns on that money.
EGX:BIOCLong
by atuumra
1
BICO risen from 27 to 41 in 5 monthsRapid change with almost certain assistance from its parent company What happened during the past period is like a miracle. The company transformed after the first quarter results showed huge losses and embezzlement charges that resulted in restructuring. After the distribution of closed dividends per share was suspended at 0.75 until liquidity was available, and liquidity was available quickly. I believe that financing was provided by the parent company in exchange for an export share and benefiting from the currency difference after the delay in the Medicine Authority’s decision to move the exchange rate. The pending dividends were issued to shareholders and we await the second-quarter results, which look promising I expect the stock to rise to 30 pounds during the month of 8, and the trend is towards 40 in January 2025.
EGX:BIOCLong
by atuumra
BIOC Trying To Fill Gap But Can It This Time?Looks like Biocept BIOC is making another technical move on more information from the company's website about its COVID testing. Apparently people on social are talking about updates that the company is doing COVID testing now. Company site specifically stating: "To support public health efforts, Biocept is performing COVID-19 testing. If you’re in need of testing, please consult with your doctor or authorized healthcare provider as Biocept will need them to order and collect the specimen for COVID-19 testing, per FDA guidance." It's interesting that this is being pointed out. I looked at WayBackMachine and see some updates but nothing that drastic. Either way, it seems like it was enough to get the juices flowing for some people on twitter. Guess we'll see what happens next. Chart has been riding the same support and testing the upper end of that previous gap. Who's placing bets on the over (going up) or the under (coming back down)?
B
by PennyStocks101
BIOC - Another Round of DilutionSurprised by another cash raise by BIOC. After the opening price crash again, and subsequent rise to the low $0.50's, had to take some risk off. Holding a smaller position and may accumulate if price action warrants it. If the company is going to use these funds to expand their burgeoning commercial operations this could be great for future growth. However Biocept Inc. management also stated that this will allow them to be funded through Dec. 2020. So this could be funding to stay alive for a few more months, or a proper cash raise for later explosive growth. JMO GL
BLong
by DawgTrading
2
BIOC Still Failing To FillCOMMENTARY BIOC is one of those penny stocks that have individual, good days. But when it comes to putting together a string of bullish action, it has yet to reach that milestone. Furthermore, though volume is good, the company still needs to execute further in my opinion. Either way. It's a good day today but would like to put this on a 30 day time clock and see where things are, at that time. QUOTE "On Tuesday (1-14) the company reported that its Target Selector™ assays are now available to doctors. The goal is for these doctors to use the Target Selector™ to evaluate cerebrospinal fluid of patients and check for the presence of circulating tumor cells for patients with breast or lung cancer suspected of brain or nervous system metastases.According to the company, the presence of tumor cells in the central nervous system might indicate brain metastases that can happen when cancer has spread to these locations. Thanks to this update, shares of Biocept rallied." QUOTE Source: Top Penny Stocks To Watch Right Now; 1 Up Over 100% Since November
B
by PennyStocks101
Biocept - Buy the negativity. The revenue doesn't mind. Biocept has the best-in-breed liquid biopsy testing in the Immuno-Oncology space. Market cap is 70 million, but it's going to be several billion in a few years if they don't get bought out first. Revenue in the second quarter ended 6/30/2016 increased 8 fold to 663,000 from 77,000 last year. This revenue only included half of June for their commerical launch of its PD-L1 protein expression test in mid-June. Frankly, I’m surprised that they didn’t burn through a lot more cash and issue a lot more shares considering their disastrous dilution last year. Their expenses didn’t go up as much as I was expecting either, and they’re sitting on $3.8 million in cash.
BLong
by mchedester
1